Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
about
The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysisTargeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.
P2860
Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immune responses to WT1 in pat ...... eic stem cell transplantation.
@en
type
label
Immune responses to WT1 in pat ...... eic stem cell transplantation.
@en
prefLabel
Immune responses to WT1 in pat ...... eic stem cell transplantation.
@en
P2093
P2860
P356
P1476
Immune responses to WT1 in pat ...... eic stem cell transplantation.
@en
P2093
Alf Spitschak
Anita Schmitt
Anthony D Ho
Carsten Hirt
Jochen Greiner
Mathias Freund
Michael Schmitt
Rosaely Casalegno-Garduño
P2860
P304
P356
10.1002/IJC.29909
P577
2015-10-31T00:00:00Z